---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022628"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:30:45.786450+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports positive VAX-24 Phase 1/2 data; Q3 net loss $57.9M, cash $366.2M plus $650.7M offering

## Summary
- Q3 net loss $57.9M (vs $26.6M YoY); R&D $47.7M (up from $20.4M) on Phase 3/IND activities.
- Cash $366.2M at Sep 30, plus ~$650.7M net from Oct follow-on offering.
- VAX-24 Phase 1/2 met endpoints; at 2.2mcg dose, non-inferiority for all 20 PCV20 serotypes, 16 higher, 4 superior.
- Expect VAX-24 Phase 2 data in 65+ in H1 2023; infant IND in H1 2023; VAX-XP IND in H2 2023.
- Appointed Mark Wiggins as CBO and Jakub Simon as CMO.

## SEC filing metadata
- accession: 0000950170-22-022628
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/0000950170-22-022628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/pcvx-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022628
- JSON: https://secwatch.observer/filing/0000950170-22-022628.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022628.txt

## Key facts
- Earnings Releases
  Vaxcyte, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 7, 2022, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/0000950170-22-022628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.